Plant from Cuban-Chinese Joint Venture Opens in Jilin Province
A modern plant from the Cuban-Chinese joint venture ChangHeber opened today in Changchun to produce the Hib vaccine, in which Cuban spokesmen consider an example of the bilateral cooperation in the field of biotechnology.
The ceremony at the headquarters located in the capital of Jilin province was attended by Cuba's First Vice President Miguel Diaz Canel, who began Monday, June 17, an official visit to China that will conclude today. The accompanying delegation comprises Leonardo Andollo, deputy chief of the Permanent Commission for the Implementation and Development, and Deputy Foreign Minister Rogelio Sierra Diaz.
The ChangHeber was opened in 2003, and currently produces more than 180 biotechnological products, including interferon.
The new facility is related to the production of the vaccine against Haemophilus influenzae, a bacterium that produces serious infectious diseases in the first years of life, mainly in brain and lungs.
This joint entity includes Cuban Heberbiotec SA, the Chinese Institute of Biological Products in Changchun, and the Jilin Boyce Technology Company.
Its fundamental objectives were to produce in China, through a total transfer of technology, a homogenous recombinant interferon alpha 2B, of demonstrated superior quality, which would be the first liquid formulation, free of human albumin produced in that Asian country.
This is the second joint venture with technology that produces products with Cuban biotechnological technology in China, the first of which BIOTECH Pharmaceutical Co. LTD (BPL), of the Molecular Immunology Center, with 10 years of existence.
The ceremony at the headquarters located in the capital of Jilin province was attended by Cuba's First Vice President Miguel Diaz Canel, who began Monday, June 17, an official visit to China that will conclude today. The accompanying delegation comprises Leonardo Andollo, deputy chief of the Permanent Commission for the Implementation and Development, and Deputy Foreign Minister Rogelio Sierra Diaz.
The ChangHeber was opened in 2003, and currently produces more than 180 biotechnological products, including interferon.
The new facility is related to the production of the vaccine against Haemophilus influenzae, a bacterium that produces serious infectious diseases in the first years of life, mainly in brain and lungs.
This joint entity includes Cuban Heberbiotec SA, the Chinese Institute of Biological Products in Changchun, and the Jilin Boyce Technology Company.
Its fundamental objectives were to produce in China, through a total transfer of technology, a homogenous recombinant interferon alpha 2B, of demonstrated superior quality, which would be the first liquid formulation, free of human albumin produced in that Asian country.
This is the second joint venture with technology that produces products with Cuban biotechnological technology in China, the first of which BIOTECH Pharmaceutical Co. LTD (BPL), of the Molecular Immunology Center, with 10 years of existence.
Source:
Prensa Latina
Date:
19/06/2013
